SG11201805120YA - Zika virus vaccine - Google Patents

Zika virus vaccine

Info

Publication number
SG11201805120YA
SG11201805120YA SG11201805120YA SG11201805120YA SG11201805120YA SG 11201805120Y A SG11201805120Y A SG 11201805120YA SG 11201805120Y A SG11201805120Y A SG 11201805120YA SG 11201805120Y A SG11201805120Y A SG 11201805120YA SG 11201805120Y A SG11201805120Y A SG 11201805120YA
Authority
SG
Singapore
Prior art keywords
valneva
vienna
international
austria gmbh
gmbh
Prior art date
Application number
SG11201805120YA
Other languages
English (en)
Inventor
Calzado Jana Barbero
Mario Nebenführ
Robert Schlegl
Michael Weber
Jürgen Wruss
Original Assignee
Valneva Austria Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57821924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201805120Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Valneva Austria Gmbh filed Critical Valneva Austria Gmbh
Publication of SG11201805120YA publication Critical patent/SG11201805120YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24163—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201805120YA 2015-12-23 2016-12-23 Zika virus vaccine SG11201805120YA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP15202585 2015-12-23
EP16161068 2016-03-18
EP16176049 2016-06-23
EP16176025 2016-06-23
EP16182845 2016-08-04
PCT/EP2016/082664 WO2017109225A1 (en) 2015-12-23 2016-12-23 Zika virus vaccine

Publications (1)

Publication Number Publication Date
SG11201805120YA true SG11201805120YA (en) 2018-07-30

Family

ID=57821924

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201805120YA SG11201805120YA (en) 2015-12-23 2016-12-23 Zika virus vaccine

Country Status (19)

Country Link
US (13) US10744194B2 (pl)
EP (8) EP3393509B1 (pl)
JP (1) JP6949027B2 (pl)
KR (1) KR20180097558A (pl)
CN (2) CN115381934A (pl)
AU (1) AU2016375338B2 (pl)
BR (1) BR112018012873A2 (pl)
CA (1) CA3009278A1 (pl)
DK (1) DK3393510T3 (pl)
ES (2) ES2950887T3 (pl)
FI (1) FI3393510T3 (pl)
HR (1) HRP20230273T1 (pl)
HU (1) HUE061679T2 (pl)
LT (1) LT3393510T (pl)
MX (1) MX2018007627A (pl)
PL (1) PL3393510T3 (pl)
SG (1) SG11201805120YA (pl)
SI (1) SI3393510T1 (pl)
WO (6) WO2017109224A1 (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
MX2018000689A (es) * 2015-07-16 2018-09-06 Bharat Biotech Int Ltd Composiciones de vacuna.
WO2017109224A1 (en) 2015-12-23 2017-06-29 Valneva Se Virus purification
US11344615B2 (en) * 2016-07-08 2022-05-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nucleic acids encoding chimeric dengue/Zika viruses optimized for growth and stability in vero cells
CA3073234A1 (en) 2017-09-21 2019-03-28 Valneva Se Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3
CN111526885A (zh) * 2017-11-03 2020-08-11 武田疫苗股份有限公司 寨卡疫苗和免疫原性组合物及其使用方法
CN107988239B (zh) * 2017-11-29 2021-03-19 南方医科大学 一种寨卡病毒的重组基因及其制备方法和应用
JP2021505549A (ja) * 2017-11-30 2021-02-18 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. ジカワクチン及び免疫原性組成物、ならびにその使用方法
CN107904215B (zh) * 2017-12-27 2021-07-27 华农（肇庆）生物产业技术研究院有限公司 一种禽流感病毒的全悬浮培养方法
CN110156880B (zh) * 2018-02-13 2022-12-16 吴夙钦 兹卡病毒疫苗组合物及其应用
TWI658848B (zh) * 2018-02-13 2019-05-11 國立清華大學 茲卡病毒疫苗組合物及其應用
EA202092216A1 (ru) 2018-03-26 2021-06-11 Бёрингер Ингельхайм Энимал Хелс Ю-Эс-Эй Инк. Способ получения иммуногенной композиции
CN108676780B (zh) * 2018-07-24 2021-08-10 华中农业大学 一种高效分离猪肠道冠状病毒的方法
CN109337876A (zh) * 2018-10-15 2019-02-15 北京世纪元亨动物防疫技术有限公司 一种猪流行性腹泻病毒的纯化方法
WO2020106358A1 (en) 2018-11-20 2020-05-28 Takeda Vaccines, Inc. Novel anti-zika virus antibodies and uses thereof
CN109627297B (zh) * 2018-12-29 2022-06-14 复旦大学 来自寨卡病毒e蛋白的中和表位及其应用
JP2022523044A (ja) * 2019-01-22 2022-04-21 ブルーバード バイオ， インコーポレイテッド ウイルスベクターを製造するための方法及びシステム
US20220211836A1 (en) * 2019-05-08 2022-07-07 Takeda Vaccines, Inc. Inactivated virus compositions and zika vaccine formulations
EP4010016A1 (en) 2019-08-09 2022-06-15 Valneva SE Single shot chikungunya virus vaccine
BR112022002082A2 (pt) 2019-08-09 2022-04-12 Valneva Se Formulações de vacina contra o chikungunya
EP4028511A1 (en) 2019-09-09 2022-07-20 Valneva Austria GmbH Inactivation process for viruses
KR102243295B1 (ko) * 2019-11-15 2021-04-23 강원대학교산학협력단 지카바이러스의 외피 단백질을 포함하는 재조합 백신 조성물
KR102365464B1 (ko) * 2019-12-24 2022-02-22 강원대학교산학협력단 지카바이러스 재조합 서브유닛 백신의 개발 및 이의 제조방법
WO2021158815A1 (en) * 2020-02-05 2021-08-12 New York Blood Center, Inc. Zika virus immunogenic compositions
EP3895729A1 (en) 2020-03-01 2021-10-20 Valneva Austria GmbH Cpg-adjuvanted sars-cov-2 virus vaccine
WO2021176434A1 (en) 2020-03-01 2021-09-10 Valneva Austria Gmbh Cpg-adjuvanted sars-cov-2 virus vaccine
CN115380042A (zh) * 2020-03-03 2022-11-22 梅奥医学教育和研究基金会 寨卡病毒多肽
TW202203967A (zh) 2020-04-06 2022-02-01 奧地利商瓦爾尼瓦奧地利有限責任公司 不活化ＳＡＲＳ—ＣｏＶ—２病毒疫苗
WO2021236225A1 (en) 2020-05-20 2021-11-25 Takeda Vaccines, Inc. Method for detection of zika virus specific antibodies
EP4153222A1 (en) 2020-05-20 2023-03-29 Takeda Vaccines, Inc. Method for detection of zika virus specific antibodies
US20230204567A1 (en) 2020-05-20 2023-06-29 Takeda Vaccines, Inc. Method for determining the potency of antigens
WO2023148256A1 (en) 2022-02-02 2023-08-10 Valneva Austria Gmbh Inactivated sars-cov-2 virus vaccine

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US86061A (en) * 1869-01-19 Improved horse-power
EP1604685B1 (en) 1997-08-28 2012-02-22 CJ Cheiljedang Corporation An attenuated Japanese encephalitis virus
ATE471983T1 (de) * 1998-09-02 2010-07-15 Us Gov Health & Human Serv Dengue viren, die in mosquitos nicht replizieren, zur verwendung als impfstoff
CA2410948C (en) 2000-05-31 2012-07-17 Chiron Corporation Method for the purification of alphavirus replicon particles
WO2002074963A1 (en) * 2001-03-16 2002-09-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt Dengue viruses that are replication defective in mosquitos for use as vaccines
US7871814B2 (en) * 2001-05-10 2011-01-18 The Regents Of The University Of California Recombinant bicistronic flaviviruses and methods of use thereof
ES2562456T3 (es) 2003-03-24 2016-03-04 Valneva Austria Gmbh Uso de un adyuvante que induce una respuesta inmune Th1 para mejorar las respuestas inmunes
BRPI0716145B1 (pt) * 2006-09-01 2021-06-22 Bharat Biotech International Limited Composição de vacina e método para preparar uma composição de vacina para o vírus chikungunya
WO2009048633A2 (en) 2007-10-11 2009-04-16 The Board Of Regents Of The University Of Texas System Chimeric chikungunya virus and uses thereof
JP5773366B2 (ja) * 2008-04-21 2015-09-02 ティシュー リジェネレイション セラピューティックス、インコーポレイテッド 生物学的又は化学的作用物質に対する予防又はそれらの治療のために遺伝子改変されたヒト臍帯血管周囲細胞
CN107574156A (zh) * 2008-11-26 2018-01-12 美国国有健康与人类服务部 类病毒组合物颗粒及其使用方法
WO2010085358A2 (en) * 2009-01-23 2010-07-29 The Board Of Regents Of The University Of Texas System Flaviviruses expressing the prm, e, and ns1 proteins of other flaviviruses and uses thereof
WO2011101465A1 (en) * 2010-02-19 2011-08-25 Intercell Ag Ic31 nanoparticles
PT3269386T (pt) 2011-12-06 2022-12-05 Valneva Austria Gmbh Compostos de alumínio para utilização em terapêuticas e vacinas
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
WO2016145149A1 (en) 2015-03-11 2016-09-15 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research Combination purified inactivated vaccine for flaviviruses
MX2018000689A (es) * 2015-07-16 2018-09-06 Bharat Biotech Int Ltd Composiciones de vacuna.
WO2017109224A1 (en) 2015-12-23 2017-06-29 Valneva Se Virus purification
CN105749268B (zh) 2016-04-11 2020-09-11 北京科兴中维生物技术有限公司 一种灭活的寨卡病毒疫苗
CA3073234A1 (en) 2017-09-21 2019-03-28 Valneva Se Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3

Also Published As

Publication number Publication date
EP3393508B1 (en) 2023-06-07
EP3393510A1 (en) 2018-10-31
EP3393506A1 (en) 2018-10-31
US20220273786A1 (en) 2022-09-01
US11331382B2 (en) 2022-05-17
HRP20230273T1 (hr) 2023-04-28
ES2941967T3 (es) 2023-05-29
WO2017109224A1 (en) 2017-06-29
EP3393508C0 (en) 2023-06-07
CA3009278A1 (en) 2017-06-29
EP4357355A2 (en) 2024-04-24
AU2016375338A1 (en) 2018-07-05
US11524064B2 (en) 2022-12-13
WO2017109229A1 (en) 2017-06-29
HUE061679T2 (hu) 2023-08-28
US20200197506A1 (en) 2020-06-25
EP3393510B1 (en) 2023-02-22
KR20180097558A (ko) 2018-08-31
US20230226165A1 (en) 2023-07-20
US20240108712A1 (en) 2024-04-04
US10660950B2 (en) 2020-05-26
WO2017109225A1 (en) 2017-06-29
MX2018007627A (es) 2019-02-14
BR112018012873A2 (pt) 2018-12-04
WO2017109228A1 (en) 2017-06-29
EP3393509C0 (en) 2024-02-28
EP3393506C0 (en) 2024-03-13
EP3393508B9 (en) 2023-09-27
PL3393510T3 (pl) 2023-06-26
LT3393510T (lt) 2023-03-27
US20180362936A1 (en) 2018-12-20
US10744194B2 (en) 2020-08-18
US20180369359A1 (en) 2018-12-27
AU2016375338B2 (en) 2021-11-04
US20180362937A1 (en) 2018-12-20
EP4253403A3 (en) 2023-12-27
EP3393507B1 (en) 2024-02-07
JP2019504030A (ja) 2019-02-14
EP3393506B1 (en) 2024-03-13
US20210093707A1 (en) 2021-04-01
EP4253403A2 (en) 2023-10-04
US10537630B2 (en) 2020-01-21
EP4218807A3 (en) 2023-09-06
EP3393509B1 (en) 2024-02-28
SI3393510T1 (sl) 2023-04-28
CN108697785A (zh) 2018-10-23
US20180371027A1 (en) 2018-12-27
ES2950887T3 (es) 2023-10-16
EP3393508A1 (en) 2018-10-31
FI3393510T3 (fi) 2023-03-22
US20200384099A1 (en) 2020-12-10
DK3393510T3 (da) 2023-03-13
EP4218807A2 (en) 2023-08-02
WO2017109227A1 (en) 2017-06-29
US20230056142A1 (en) 2023-02-23
EP3393507A1 (en) 2018-10-31
US20190008945A1 (en) 2019-01-10
CN108697785B (zh) 2022-08-02
US11406700B2 (en) 2022-08-09
US20200017555A9 (en) 2020-01-16
US20200368342A1 (en) 2020-11-26
US11219681B2 (en) 2022-01-11
US11207397B2 (en) 2021-12-28
US10639365B2 (en) 2020-05-05
CN115381934A (zh) 2022-11-25
US11951163B2 (en) 2024-04-09
JP6949027B2 (ja) 2021-10-20
EP3393509A1 (en) 2018-10-31
WO2017109223A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
SG11201805120YA (en) Zika virus vaccine
SG11201906763RA (en) Pyrrolo [1,2-b] pyridazine derivatives
SG11201807912SA (en) Vaccine against rsv
SG11201804411TA (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
SG11201804814YA (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
SG11201907034PA (en) Methods of treating influenza
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201807913XA (en) Stabilized soluble pre-fusion rsv f proteins
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201811470PA (en) Pyrazolopyrimidine derivatives as kinase inhibitor
SG11201805570WA (en) Systems and methods for long term transdermal administration
SG11201805001UA (en) Method of treating influenza a
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201807051VA (en) Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
SG11201810078PA (en) Stabilized pre-fusion rsv f proteins
SG11201900021PA (en) Methods and compositions for the treatment of cancer
SG11201805204WA (en) Nicotine particle capsule
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201810786RA (en) [bis(trihydrocarbylsilyl)aminosilyl]-functionalized styrene and a method for its preparation
SG11201807977XA (en) Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
SG11201807404XA (en) Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders